NEW YORK (GenomeWeb) – Thermo Fisher Scientific and BioAnalytix today announced they will develop advanced analytical profiling platforms and applications for characterizing biologic and biosimilar drugs.

Minor differences in the structures of biological drugs can significantly affect their safety and efficacy, and sophisticated analytic workflows are necessary for accurate characterization. Thermo Fisher and BioAnalytix aim to develop analytical profiling standards in order to support and accelerate the development of such therapeutics, they said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.

Retraction Watch's Ivan Oransky and Adam Marcus report that Harvard Medical School and Brigham and Women's Hospital have recommended that more than 30 papers from a former researcher be retracted.

Thomas Steitz, who won the 2009 chemistry Nobel Prize for his ribosome work, has died, the Washington Post reports.

In PLOS this week: mechanisms for genes implicated in coronary artery disease, rumen microbes and host genetics influence cow methane production, and more.